Shares of health-care companies ticked down as traders rotate into more rate-sensitive areas. A federal jury in Chicago ordered drug maker AbbVie to pay more than $140 million in damages to a Tennessee man who suffered a heart attack following use of its testosterone-replacement therapy AndroGel. Bayer has stopped a late stage study for the use of blood-thinning drug Xarelto, saying it showed no improved efficacy compared with another treatment using aspirin.
-Rob Curran, email@example.com
Continue Reading Below
(END) Dow Jones Newswires
October 06, 2017 16:31 ET (20:31 GMT)